Sequencing IO and radiotherapy in nasopharyngeal carcinoma

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on the potential benefits of integrating PD-1 immunotherapy (IO) with chemo-radiotherapy in the treatment of nasopharyngeal carcinoma (NPC). Utilizing anti-PD-1-agents throughout the treatment course or in the adjuvant phase alone can improve survival in patients with NPC, and combining PD-1 blockades with chemotherapy and radiotherapy may enhance cytotoxic T-cell activity and anti-tumor responses. This This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next